(Linezolid 600 mg Tablets)
INFULID Tablets contains Linezolid. It has activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus pneumoniae (PRSP).
Linezolid which is a synthetic antibacterial agent of the oxazolidinone class.
INFULID Tablets can be used in the treatment of the following conditions:
- Nosocomial and community acquired pneumonia
- Complicated and uncomplicated skin and skin structure infections including MRSA
- Diabetic foot infections
- Vancomycin-Resistant Enterococcus Faecium Infections.
- Multi-drug resistant tuberculosis & extensively drug-resistant tuberculosis.
Adults and children (12yrs and above): One INFULID Tablet twice a day for 10-14 days (14-28 days for VRE infections). One INFULID Tablet twice a day for 4-6 weeks followed by one INFULID Tablet a day for extensively drug resistant tuberculosis.
Linezolid selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process.